44 results
8-K
EX-99.1
URGN
UroGen Pharma Ltd
13 Jun 24
Regulation FD Disclosure
10:51am
patients an outpatient setting, or innovation even at home 9 1. ACS Cancer Facts & Figures 2023; SEER, AUA/SUO joint guideline; Babjuk et al. European … market population, indicating potential the first FDA ripe for innovation to reduce burden for large approved medicine population of LG-IR-NMIBC
8-K
EX-99.1
URGN
UroGen Pharma Ltd
4 Mar 24
Regulation FD Disclosure
7:00am
placement LG-IR-NMIBC market data package from 3 with experienced ripe for innovation trials and 565 patients biotech investors
ENVISION Trial Design
8-K
EX-99.1
wlhsg0y 0cs6j4o
7 Feb 24
Regulation FD Disclosure
4:15pm
8-K
EX-10.1
rvcpw7el6vs844
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am
8-K
EX-99.2
63do dclgokallve
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am
8-K
EX-99.1
h5e8px
13 May 21
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
7:40am